Products
Automated vision-testing kiosks face concerns amid national expansion
With Eyebot’s 90-second vision tests rolling out across the country, the AOA is voicing words of caution over the self-administered kiosks.
Business
CSI Dry Eye Innovations unveils new branding and software patent
Rebrand paves way for potential future dry eye product launches to join its flagship, AI-based program: CSI Dry Eye Software.
Research
Study demonstrates accuracy of new platform for comparing AI-based DR screening systems
New testing platform allows for comparison of effectiveness and fairness in commercial AI systems.
Pipeline
FDA grants Fast Track designation for Drug Farm's ROSAH syndrome asset
S
Research
Pseudoexfoliation glaucoma is most prevalent among Indigenous populations in the US
Study finds American Indian or Alaska Native patients are impacted by PXG and PG nearly threefold more than the general U.S. population.
Products
FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop
First and only combination drop of carbachol and brimonidine tartrate achieves miosis within 30 minutes and lasts up to 10 hours following once-daily dosing.
Products
FDA approves Glaukos' iDose TR for repeat treatment labeling
Travoprost intracameral implant can now be re-administered using a repeat treatment protocol—enabling greater flexibility in glaucoma patient management.
Research
Cannabis implicated in ocular inflammatory disease development
Cannabis use associated with higher risk of developing uveitis and other posterior segment diseases.
Products
FDA approves Alembic's difluprednate 0.05% generic
Generic version of Sandoz’s Durezol is indicated for postop pain and inflammation as well as endogenous anterior uveitis.
Products
Nidek launches Phantom Open-field Refraction System
Device corrects refractive errors with virtual lenses simulating the same properties as real lenses—in under 5 minutes.
Research
Conflicting evidence surrounds astigmatism's role in myopia
Study highlights need for further investigation into the impact of astigmatism on myopia onset and progression.
Pipeline
FDA clears Novaliq's IND for NIAU phase 2 trial
Clearance enables FIH study of potentially the first steroid-free eye drop for controlling IOI among non-infectious anterior uveitis patients.
Pipeline
Novartis's ianalumab earns FDA Breakthrough Therapy designation for Sjögren’s disease
Fully human monoclonal antibody is delivered as a monthly subcutaneous injection; company plans to submit for global approval in early 2026.
Products
OCuSOFT launches Retaine Omega Forte for dry eye
New nutritional supplement offers a daily dose of omega-3 essential fatty acids.
Business
Leadership watch: Emmecell, ABO, Outlook, and Heidelberg make changes
Leadership changes are underway in the eyecare space—and we’ve got the latest.
Pipeline
FDA grants Orphan Drug designation to BlueRock's RP cell therapy
Marks second designation for OpCT-001; includes tax credits for qualified clinical testing and, if approved, 7 years of U.S. market exclusivity.
Research
New QLOSI safety data supports drop as pupil selective for presbyopia
Head-to-head trial finds pilocarpine 0.4% resulted in no significant changes in ciliary muscle or lens thickness following dosing.
Pipeline
BioAge Labs expands into DME clinical program for oral inhibitor asset
Preclinical evidence on NLRP3 inhibitor BGE-102 shows potential for therapeutic retinal exposure, with an initial POC trial to kick off later this year.
Events
Registration now open for Eyes On Dry Eye 2026
Largest virtual dry eye event of the year offers up to 7 hours of free CE from leading clinical experts.
Research